Fate Therapeutics Highlights Positive Durability of Response Data from FT516 Phase 1…
6 of 10 Patients Naïve to Treatment with Autologous CAR T-cell Therapy Continue in Ongoing Response at Median Follow-up of 9.1 Months, including 4 Patients with >6 Months Follow-up, at…